ECU
MRVI icon

Eisler Capital (US)’s Maravai LifeSciences MRVI Stock Holding History

Eisler Capital (US)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-116,381
Closed -$833K – 603
2024
Q2 		$833K Buy
+116,381
New +$1M 0.01% 474

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Eisler Capital (US)'s MRVI Position: Q3 2024 in Review

Eisler Capital (US) sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 116,381 shares — an estimated $833K sold.

Eisler Capital (US) first reported a position in MRVI in Q2 2024 and held it in 1 quarter. The position peaked at $833K in Q2 2024. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

  • Eisler Capital (US) reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 116,381 Maravai LifeSciences shares in Q3 2024, an estimated $833K.
  • Eisler Capital (US) first reported a position in Maravai LifeSciences in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Maravai LifeSciences position peaked at $833K in Q2 2024.
  • 217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.